|Publication number||US5520786 A|
|Application number||US 08/471,745|
|Publication date||28 May 1996|
|Filing date||6 Jun 1995|
|Priority date||6 Jun 1995|
|Also published as||CA2177753A1, CA2177753C, DE69622936D1, DE69622936T2, EP0747984A2, EP0747984A3, EP0747984B1|
|Publication number||08471745, 471745, US 5520786 A, US 5520786A, US-A-5520786, US5520786 A, US5520786A|
|Inventors||Michael L. Bloczynski, Paul F. Corey, Yingping Deng, Alison J. Murray, Matthew K. Musho, Hans-Ulrich Siegmund|
|Original Assignee||Bayer Corporation|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (3), Non-Patent Citations (4), Referenced by (109), Classifications (23), Legal Events (8)|
|External Links: USPTO, USPTO Assignment, Espacenet|
Analytical methods that combine the selectivity of enzymes with the sensitivity of amperometric detection are of interest to the diagnostic industry. The reduction of the nicotinamide co-enzymes (NAD and NADP) is particularly important because they are produced in reactions catalyzed by dehydrogenases. Dehydrogenase catalyzed reactions according to the equation: ##STR1## play an important role in biological cells and analytical reactions. Several hundred different dehydrogenases are known which selectively catalyze the conversion of different substrates into products. When the substrate, e.g. glucose, is oxidized, the enzymes NAD+ and/or NADP+ are reduced to NADH and NADPH respectively. These co-enzymes are a necessary element in the reaction due to their ability to act with the dehydrogenase enzyme to form an energy-transferring redox couple. The pyridine linked dehydrogenases transfer reversibly two reducing equivalents from the substrate to the oxidized form of the pyridine nucleotide; one of which appears in the reduced pyridine nucleotide as a hydrogen atom, and the other as an electron. The other hydrogen atom removed from the substrate appears as free H+ in the medium.
The co-enzymes NAD+ and NADP+ are expensive chemicals making their regeneration and reoxidation to their original state imperative if they are to be economically used in low cost, disposable, analytical devices.
NADH is oxidized directly at different base electrode materials only with high overvoltages on the order of 1 volt. However, a decrease in this overvoltage can be obtained by the adsorption of functionalities on the electrode surface which mediate the electron transfer from NADH to the electrode. Such mediators are typically selected from materials which may be reoxidized electrochemically without excessive overvoltages rendering them useful as an auxiliary system for electrochemical regeneration. Various mediator compounds suitable for this purpose are known. In U.S. Pat. No. 4,490,464 there are mentioned, by way of background, mediators such as phenazine methosulfate (PMS); phenazine ethosulphate (PES); thionine and 1,2-benzoquinone. This patent goes on to describe electrodes which are modified to catalyze the oxidation of NADH, NADPH or analogs thereof by imparting to the electrode surface as mediator a condensed aromatic ring system comprising at least three and preferably four or more condensed aromatic rings with or without heteroatoms. More particularly, this patent describes the electron exchange with the co-enzyme or analog thereof by structural elements comprising one of either alkyl phenazinium ions, phenazinium ions, phenazinones, phenoxazinium ions, phenoxazinones, phenothiazinium ions or phenothiazinones.
In J. Electroanal. Chem. 287, 61-80 (1990) there is disclosed 3-β-naphthoyltoluidine blue O (I): ##STR2## which is perhaps the most effective of the known phenothiazinium mediators generically disclosed in the '464 patent. A variety of the mediators disclosed in this patent are compared in J. Electroanal. Chem. 292, 115-138 (1990).
The phenoxazinium and phenothiazinium ions disclosed in the '464 patent are positively charged species such as (I) above and are readily distinguishable from the mediator compounds of the present invention. The phenoxaziones and phenothiazinones claimed in the '464 patent are 3H-phenothiazines (II) and 3H-phenoxazines (III): ##STR3## in which the 3-position is derivatized with a carbonyl oxygen group. They bear a structural resemblance to the compounds of the present invention in that the oxygen atoms in (II) and (III) are replaced by nitrogen atom bearing substituted phenyl rings. In reality, however, these compounds are quite different and there is no suggestion in the prior art that replacing the carbonyl oxygen of compounds (II) and (III) with a phenyl-substituted nitrogen atom would afford effective mediators.
The compounds, whose utility as mediators is taught herein, are disclosed in U.S. Pat. No. 4,710,570 which describes the "leuko" or reduced form of these dyes to be "suitable as dye-forming agents in pressure sensitive, thermographic, photothermographic and photographic imaging systems."
U.S. Pat. No. 5,264,092 discloses the mediators of the '464 patent covalently attached to polymers which are useful for the electrochemical regeneration of NADH. This patent discloses a variety of polymeric backbones to which the mediators are attached. Polymer/mediator modified electrodes are also disclosed. Certain of the mediators of the present invention also perform well when immobilized on polymers.
The present invention involves an electrode suitable for the electrochemical regeneration of the coenzymes dihydronicotinamide adenine dinucleotide (NADH), dihydronicotinamide adenine dinucleotide phosphate (NADPH) or analogs thereof, said electrode having imparted on its surface a mediator function comprising one or more mediator compounds selected from the group consisting of substituted or unsubstituted 3-phenylimino-3H-phenothiazines and 3-phenylimino-3H-phenoxizines.
FIG. 1 represents the cyclic voltammogram of 0.6 mM compound 18 in 0.6 mM PIPES buffer at pH=7.0 alone and in the presence of 5 mM NADH.
FIG. 2 shows a typical cyclic voltammogram of NADH being oxidized directly on a printed electrode.
FIG. 3 is a plot of current vs. glucose concentration at set potentials for one of the mediators of the present invention.
FIG. 4 is a plot of current vs. glucose potential using polymeric mediators.
This invention is predicated on the discovery that 3-phenylimino-3H-phenothiazines and 3-phenylimino-3H-phenoxizine compounds are useful mediators for the electrochemical regeneration (oxidation) of NADH. The mediators of the present invention can be represented by general formulae (IV) and (V). ##STR4##
It is evident that R1 and R2 in formulae IV and V can represent a variety of substituent groups without departing from the scope of the present invention. Such substituent groups are limited only by the ability of one of ordinary skill in the art to prepare stable compounds which have electrochemical properties necessary for the requisite electron transport.
For example, in the above formulae substituents R1 and R2 may be the same or different, and selected from the group consisting of hydrogen, lower alkyl, aryl, halo, haloalkyl, carboxy, carboxyalkyl, alkoxycarbonyl, aryloxycarbonyl, aromatic and aliphatic keto, alkoxy, aryloxy, nitro, dialkylamino, aminoalkyl, sulfo, dihydroxyboron (--B(OH)2) and the like. It is also intended that aliphatic and aromatic groups incorporated into R1 and R2 can themselves bear a variety of substituent groups.
The substituents R1 and R2 may serve to modulate the reduction-oxidation (redox) potential of the mediator, to vary solubility or to function as a handle for covalent attachment of the mediator to a polymer or solid support.
Compounds (IV) and (V) can be represented by a single formula (A) in which the symbol X is used to represent oxygen and sulfur: ##STR5##
Nicotinamide adenine dinucleotide (oxidized form, NAD+ ; reduced form, NADH) is the cofactor providing chemical redox function for many dehydrogenase enzymes. This cofactor is reduced during the course of the enzymatic reaction as the substrate molecule is oxidized. Amperometric biosensors seeking to use these enzymes as a means to measure substrate concentration correlate this concentration with the current generated as the cofactor is electrochemically re-oxidized. The NADH can be electrochemically re-oxidized on graphite, pyrolytic carbon, glassy carbon, platinum, gold, or a composite made from these materials, electrodes without a mediator, but this reaction occurs with several difficulties including a large overpotential and electrode fouling.
The present invention describes the first use of 3-phenylimino-3H-phenothiazines (IV) and 3-phenylimino-3H-phenoxizines (V) in the electrochemical regeneration of NADH and NADPH coenzymes or their derivatives and accordingly, encompasses a wide variety of phenothiazine and phenoxazine derivatives. The present mediators can also be used for the electrochemical regeneration of NADH and NADPH derivatives. Derivatives of NADH and NADPH include modified cofactors such as in the case where the coenzyme is attached to a polymer as described by Dolabdjian, et al in Enzyme Engineering Vol. 4, G. B. Brown and G. Manecke, eds., Plenum Press, New York, 1978, Pp. 399-400 or covalently attached to the dehydrogenase enzyme as described by M. Persson, et al in Biotechnology 9, Pp. 280-284 (1991) or synthetic analogs bearing other substituents so long as they function as the cofactor for the dehydrogenase enzyme. These references are incorporated herein by reference. In a preferred embodiment, the mediator is covalently bonded to Gantrez, i.e. poly(methylvinyl ether-co-maleic anhydride). Gantrez can be represented by the formula ##STR6## where n is preferably from about 120 to about 500.
The mediator compounds useful in this invention are depicted by general formulae IV and V. The structures of the compounds synthesized and tested are numbered with Arabic numerals and appear in the first column of Table 1. Columns 2-7 of Table 1 summarize results of mediator evaluations as described in Examples III and IV.
TABLE 1 Mediator Structures and Activities NADH Titration on GRE Glucose Titration on Sensor Compound Eox o Potential Slope Eox.sup. o Potential Slope ##STR7## 55 mv 155 mv 0.0061 ##STR8## 108 mv 210 mv 0.0072 ##STR9## 79 mv36 mv 160 mv200 mv 0.00420.0125 ##STR10## 62 mv101 mv 162 mv200 mv 0.00770.0109 ##STR11## 71 mv92 mv 171 mv200 mv 0.00660.0079 ##STR12## 143 mv130 mv ##STR13## 72 mv74 mv 160 mv200 mv 0.00390.0132 ##STR14## 136 mv 250 mv 0.0042 ##STR15## 141 mv 250 mv 0.0056 ##STR16## 24 mv 100 mv 0.0059 125 mv 0.0145 ##STR17## 57 mv 150 mv 0.0061 160 mv 0.0192 ##STR18## 92 mv 200 mv 0.0094 ##STR19## 71 mv 200 mv 0.0072 150 mv 0.0185 ##STR20## -20 mv 100 mv 0.0067 ##STR21## 189 mv &-120 mv -15 mv 300 mv 0.0016 ##STR22##86 mv 400 mv 0.0142 ##STR23##138 mv 100 mv200 mv300 mv 0.01560.02030.0205 ##STR24## 27 mv 200 mv 0.0090 -14 mv 100 mv300 mv 0.08480.0962 ##STR25## ##STR26##-116 mv 100 mv 0.079 ##STR27##
Among those phenothiazines and phenoxazines which have been prepared and found to have suitable properties as NADH mediators are 3-(4'-chloro-phenylimino)-3H-phenothiazine, 3-(4'-diethylamino-phenylimino)-3H-phenothiazine, 3-(4'-ethyl-phenylimino)-3H-phenothiazine, 3-(4'-trifluoromethyl-phenylimino)-3H-phenothiazine, 3-(4'-methoxycarbonyl-phenylimino)-3H-phenothiazine, 3-(4'-nitro-phenylimino-3H-phenothiazine, 3-(4'-methoxy-phenylimino)-3H-phenothiazine, 7-acetyl-3-(4'-methoxycarbonylphenylimino)-3H-phenothiazine, 7-trifluoromethyl-3-(4'-methoxycarbonyl-phenylimino)-3H-phenothiazine, 3-(4'-ω-carboxy-n-butyl-phenylimino)-3H-phenothiazine, 3-(4'-aminomethyl-phenylimino)-3H-phenothiazine, 3-(4'-(2"-(5"-(p-aminophenyl)-1,3,4-oxadiazoyl)phenylimino)-3H-phenothiazine, 3-(4'-β-aminoethyl-phenylimino)-3H-phenothiazine, 6-(4'-ethylphenyl)amino-3-(4'-ethylphenylimino)-3H-phenothiazine, 6-(4'-[2-(2-ethanoloxy)ethoxy]-ethoxyphenyl)amino-3-(4'-[2-(2-ethanoloxy)ethoxy]ethoxyphenylimino)-3H-phenothiazine, 3-(4'-[2-(2-ethanoloxy)ethoxy]ethoxy-phenylimino)-3H-phenothiazine, 3-(4'-phenylimino)-3H-phenothiazineboronic acid, 3-(3',5'-dicarboxy-phenylimino)-3H-phenothiazine, 3-(4'-carboxyphenylimino)-3H-phenothiazine, 3-(3',5'-dicarboxy-phenylimino)-3H-phenoxazine, 3-(2',5'-phenylimino)-3H-phenothiazinedisulfonic acid, and 3-(3'-phenylimino)-3H-phenothiazinesulfonic acid.
The method of practicing the invention is further illustrated by the following examples.
In general, the synthesis of the compounds useful as mediators in the present invention involves the oxidative coupling of an aniline with a phenothiazine or a phenoxazine. The synthesis of the unsubstituted 3-phenylimino-3H-phenothiazine was reported in Liebigs Ann. Chemn. 322, 39 (1902) whereas the synthesis of two other analogs is reported in U.S. Pat. No. 4,710,570. Both of these references are incorporated herein by reference. The general synthetic scheme for preparing these compounds is presented in Scheme I in which compound 18 from Table I is exemplified: ##STR28## The synthesis of specific compound from Table I (compounds 4, 12 and 20) was carried out as follows:
Phenothiazine (2.0 g, 10 mmole) and 4-aminobenzotrifluoride (1.77 g, 11 mmole) were dissolved in methanol (MeOH) (100 mL) with warming to 45° C., treated with a solution of I2 (5.0 g, 19.4 mmole) in MeOH (80 mL) in one portion and allowed to stir for 3 h at 45° C. The reaction mixture was filtered and the collected solid was washed with MeOH (100 mL). The solid was dissolved in CHCl3 (60 mL) containing triethylamine (NEt3) (6 mL) then this solution was diluted with hexane (200 mL) and chilled in an ice bath for 2 h. The purple solid that separated was collected by filtration and redissolved in CHCl3 /NEt3 (10:1, v:v) (50 mL) and chromatographed on silica gel (250 g) using CHCl3 /acetone (96:4, v:v) development. The purple product band was collected and evaporated to dryness in vacuo to afford 4 (0.26 g, 7.3%) with mp=207°-8° C.
Anal. Calcd. for C19 H11 N2 F3 S: C, 63.84; H, 3.38; N, 7.84. Found: C, 63.69; H, 3.26; N, 7.84.
Phenothiazine (1.0 g, 5.0 mmol) and 5-aminoisophthalic acid (0.9 g, 5.0 mmol) were dissolved in MeOH (200 mL), cooled to 10° C. and treated with 1 M aqueous AgNO3 (30 mL, 30 mmol). After stirring at 10° C. for 30 minutes H2 O (40 mL) was added and stirring continued for an additional 5 minutes. The solid product was then collected by filtration and washed with H2 O (50 mL). The solid was dissolved in MeOH (500 mL) containing concentrated aqueous NH4 OH (10 mL), stirred for 20 minutes then filtered to remove Ag. The filtrate was concentrated to ca. half its original volume under reduced pressure and refrigerated overnight at 5° C. The mixture was then filtered through Celite (Celite Corp.) and concentrated in vacuo until solid began to separate. The resulting solution (ca. 100 mL) was again filtered through Celite, diluted with ethyl acetate (900 mL) and allowed to stand for 15 minutes. The red solid that separated was collected by filtration, washed with ethyl acetate and dried to give 18(1.55 g, 82.5%).
Phenoxazine (0.92 g, 5 mmole) was dissolved in tetrahydrofuran (THF) (10 mL) and stirred at ambient temperature with a solution of 5-aminoisophthalic acid (0.88 g, 4.86 mmole) in H2 O (10 mL) containing concentrated aqueous NH4 OH (1 mL). The mixture was rapidly treated with a solution of 1.0 M aqueous AgNO2 solution (13.5 mL) and stirred for 2 h, during which time a solid separated. The solid was collected by filtration and extracted three times with THF (100 mL each). The combined extracts were evaporated to dryness in vacuo to yield a dark solid (0.8 g) which was taken up in CHCl3 /MeOH (1:1, v:v) (100 mL), with warming, and chromatographed on silica gel (300 g) using CHCl3 /MeOH (2:1, v:v) development. The dark orange product band was collected and evaporated to dryness in vacuo to afford 20(0.30 g, 16.7%).
Using the procedures outlined above, one skilled in this art could synthesize a wide variety of substituted analogs of these compounds.
The synthesis of a polymeric mediator, designated herein as P-3, is representative of the method used to prepare other polymer bound mediators within the scope of the present invention. This synthesis is illustrated in Scheme 2 and the description which follows it. P-3 may be described as "40% 13 on Gantrez" because 40% of the anhydride groups on the polymer have been reacted with the amino moiety of 13. ##STR29##
A solution of GANTREZ AN-119 (ISP Technologies, Inc., Wayne, N.J.) (0.156 g, 1.0 mmol anhydride) in anhydrous N,N-dimethylformamide (DMF) (10.0 mL), maintained under an inert gas atmosphere at ambient temperature, was treated at once with a solution of 13 (0.1326 g, 0.4 mmole) and anhydrous triethylamine 0.56 mL, 4.0 mmole) in anhydrous DMF (5.0 mL). Additional DMF (3.0 mL) was used to rinse in traces of the 13 solution then the reaction mixture was allowed to stir for 1 hour. The mixture was diluted with H2 O (25 mL), stirred for 15 minutes then blended into additional H2 O (175 mL). The resulting solution was acidified with conc. HCl (3.0 ML) whereupon the product separated as a solid. The mixture was centrifuged for 20 min. at 10,400 X g and the supernatant discarded. The pellet was resuspended in 0.1 M HCl (20 mL) with sonication and centrifuged for 20 min. at 33,400 X g. The supernatant was discarded and the pellet resuspended in 100% ethanol (20 mL) with sonication, then centrifuged for 30 min. at 33,400 X g. The supernatant was discarded and the pellet was dried in vacuo to afford P-3 (0.26 g) as a black powder.
Polymeric mediators P-1 (20% 11 on Gantrez) and P-2 (20% 13 on Gantrez) are prepared analogously to P-3 except that the 0.4 mmol of 13 is replaced with 0.2 mmol of 11 or 0.2 mmol of 13 respectively.
Graphite rod electrodes (3 mm in diameter from Johnson Matthey Electronics, Ward Hill, Mass.) were prepared by polishing the electrode's surface first using a fine grit sandpaper then a suspension of ≧1 micron alumina particles. A 1-2 mM solution of the mediator in methanol was prepared and the electrode soaked in this solution for 2 minutes. The electrodes were then rinsed with water and soaked for a short time in 0.25 M phosphate buffer (pH=7.0). A current vs. voltage profile was first run to determine the cathodic and anodic peak positions vs. a Ag/AgCl reference electrode. Currents were then measured in pH=7.0 solutions containing NADH in concentrations from 20 to 200 μM, using a potential that was typically 100 mv more positive than the oxidative peak potential (E°ox) obtained in the cyclic voltammetry experiment above (actual potentials used are listed in column #3 of Table 1), and the slope of the line obtained from a least squares fit of the current vs. NADH concentration data gave the relative sensitivity of each mediator in μA/μM NADH. These slopes for various mediators are listed in the 4th column of Table 1; the greater the slope the better the mediator. For comparison, the slope obtained for 3-β-naphthoyl-toluidine blue O (I) under these conditions is 0.0075.
Experiments involving printed electrodes comprising a printed sensor card with a graphite/carbon working electrode and a silver/silver chloride reference electrode were carried out. The ink used for the graphite/carbon electrode was No. 423SS (from Acheson Colloids Co., Port Huron, Mich.) and No. 427SS silver ink (same vendor) blended with 15-25% AgCl for the silver/silver chloride reference electrode. Electrode surface area was 0.03 cm2.
Cyclic voltammetry experiments were performed on printed electrodes just as on the graphite rod electrodes. FIG. 1 shows the cyclic voltammogram of 0.6 mM compound 18 in 0.6 mM PIPES buffer at pH=7.0 alone and in the presence of 5 mM NADH. The increase in current at a potential of 26 mv in the presence of NADH is due to the oxidation of mediator that had been reduced by NADH. The mediator is reduced as it oxidizes NADH to NAD+ and is then re-oxidized electrochemically at the electrode. In effect the mediator facilitates the electrochemical oxidation of NADH at potentials considerably lower than those required to oxidize NADH directly. FIG. 2 shows a typical cyclic voltammogram of NADH being oxidized directly (no mediator) on a printed electrode. A much higher peak potential (443 mv) is apparent.
A biosensor for measuring glucose concentration uses the enzyme glucose dehydrogenase to reduce NAD+ to NADH as it oxidizes glucose to gluconolactone. Mediated electrochemical re-oxidation of the NADH to NAD+ generates a current that is proportional to the glucose concentration.
A typical glucose biosensor was fabricated as follows: A solution of 4 mM mediator in 100 mM pH=7.0 phosphate buffer containing 25 mM KCl was prepared and diluted with an equal volume of a solution composed of 1.96 g 5% Surfynol (Air Products and Chemicals, Inc., Allentown, Pa.), 0.32 g NAD, 0.70 g Glucose Dehydrogenase GDH (Toyobo), 1.44 g 0.5M PIPES buffer pH--7.0 and 5.5 mL DI H2 O. 1.75 μL of the mixture was applied to the sensor area and allowed to dry at RT for about 20 min. The electrode was assembled in a format having a small capillary gap, treated with a solution of aqueous glucose and the current measured at the potential noted in the 6th column of Table 1. This was done for samples containing glucose concentrations of 0, 50, 100, 200 and 500 mg/dL and the slope of the lisine line obtained from a least squares fit of the current vs. glucose concentration data gave the relative sensitivity of each mediator in μA/mg dL-1 glucose; the larger the slope the better the mediator. These slopes are listed in the last column of Table 1.
FIG. 3 shows the plot of current vs. glucose concentration for compound 18 at 100 mv and 300 mv potentials.
Polymeric mediators were incorporated into complete glucose biosensors as described above and the relative sensitivities are listed in the last column of Table 2.
TABLE 2______________________________________Activity of Polymeric Mediators Titra- tion onNADH Poten- on Glucose Titration SensorE°ox tial GRE E°ox Potential Slope______________________________________P-1 -26 mv 100 mv 0.0204(20% 11 - 300 mv 0.0362Gantrez)P-2 -62 mv 300 mv 0.0276(20% 13 -Gantrez)P-3 -43 mv 300 mv 0.0217(40% 13 -Gantrez)______________________________________
FIG. 4 shows the plot of current vs. glucose concentration for 3 polymeric mediators at 300 mv potential.
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4490464 *||8 Mar 1982||25 Dec 1984||Gorton Lo G||Electrode for the electrochemical regeneration of coenzyme, a method of making said electrode, and the use thereof|
|US4710570 *||30 Sep 1985||1 Dec 1987||Minnesota Mining And Manufacturing Company||Azine redox dyes and leuco azine dyes|
|US5373348 *||6 Nov 1992||13 Dec 1994||Dai Nippon Insatsu Kabushiki Kaisha||Converting device including variable electroconductivity material, and recording and detecting method using the same|
|1||*||B. Persson, A Comparative Study of 3,7 Diaminopheonxazine . . . , J. Electroanal. Chem. 292 (1990) 115 138.|
|2||B. Persson, A Comparative Study of 3,7-Diaminopheonxazine . . . , J. Electroanal. Chem. 292 (1990) 115-138.|
|3||*||Doubova et al., Polyaniline a a Cathode for O 2 . . . , Electrochimica Acta, vol. 34, No. 3, pp. 337 343, 1989.|
|4||Doubova et al., Polyaniline a a Cathode for O2. . . , Electrochimica Acta, vol. 34, No. 3, pp. 337-343, 1989.|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US5866353 *||9 Dec 1996||2 Feb 1999||Bayer Corporation||Electro chemical biosensor containing diazacyanine mediator for co-enzyme regeneration|
|US6468416||16 Jul 1998||22 Oct 2002||Sapporo Immuno Diagnostic Laboratory||Method for assaying L-phenylalanine and L-phenylalanine sensor|
|US6500571||18 Aug 1999||31 Dec 2002||Powerzyme, Inc.||Enzymatic fuel cell|
|US7163616 *||3 Sep 2002||16 Jan 2007||Bayer Corporation||Reagents and methods for detecting analytes, and devices comprising reagents for detecting analytes|
|US7244610||12 Nov 2004||17 Jul 2007||Rice University||Aerobic succinate production in bacteria|
|US7256016||1 Nov 2002||14 Aug 2007||Rice University||Recycling system for manipulation of intracellular NADH availability|
|US7439033||29 Jan 2004||21 Oct 2008||Bayer Healthcare Llc||Method and test strip for determining a fluid analyte|
|US7709261||4 Jul 2007||4 May 2010||Rice University||Recycling system for manipulation of intracellular NADH availability|
|US7862696||10 Sep 2007||4 Jan 2011||Bayer Healthcare Llc||Biosensor system having enhanced stability and hematocrit performance|
|US7935511||14 Jun 2007||3 May 2011||Rice University||Aerobic succinate production in bacteria|
|US8002965||7 Apr 2006||23 Aug 2011||Bayer Healthcare Llc||Oxidizable species as an internal reference in control solutions for biosensors|
|US8007656||22 Oct 2004||30 Aug 2011||Bayer Healthcare Llc||Enzymatic electrochemical biosensor|
|US8008037||30 Aug 2011||Roche Diagnostics Operations, Inc.||Matrix composition with alkylphenazine quaternary salt and a nitrosoaniline|
|US8022204||9 Dec 2008||20 Sep 2011||Bayer Healthcare Llc||Process of making 3-phenylimino-3H-phenothiazine|
|US8026104||21 Oct 2007||27 Sep 2011||Bayer Healthcare Llc||Transient decay amperometry|
|US8102517||12 Dec 2005||24 Jan 2012||Bayer Healthcare, Llc||Method of differentiating between blood and control solutions containing a common analyte|
|US8252523||28 Aug 2012||Bayer Healthcare Llc||Porous particle reagent compositions|
|US8262899||10 Jul 2009||11 Sep 2012||Bayer Healthcare Llc||Systems and methods including amperometric and voltammetric duty cycles|
|US8283347||9 Oct 2012||Bayer Healthcare Llc||Redox molecules and methods of making the same|
|US8317988||27 Nov 2012||Bayer Healthcare Llc||Concentration determination in a diffusion barrier layer|
|US8337691||25 Dec 2012||Bayer Healthcare Llc||Control markers for auto-detection of control solution and method of use|
|US8357797||11 Aug 2011||22 Jan 2013||Bayer Healthcare Llc||Process of making 3-phenylimino-3H-phenoxazine mediator|
|US8404100||26 Mar 2013||Bayer Healthcare Llc||Gated voltammetry|
|US8416398||21 Dec 2011||9 Apr 2013||Bayer Healthcare, Llc||Method of differentiating between blood and control solutions containing a common analyte|
|US8425757||23 Apr 2013||Bayer Healthcare Llc||Gated amperometry|
|US8470604||16 Aug 2011||25 Jun 2013||Bayer Healthcare Llc||Transient decay amperometry|
|US8535511||12 Aug 2011||17 Sep 2013||Roche Diagnostics Operations, Inc.||Methods for electrochemical analysis using matrix compositions with alkylphenazine quaternary salt and a nitrosoaniline|
|US8617835||23 Jul 2012||31 Dec 2013||Bayer Healthcare Llc||Porous particle reagent compositions, devices, and methods for biosensors|
|US8647489||28 Feb 2013||11 Feb 2014||Bayer Healthcare Llc||Gated voltammetry devices|
|US8679772 *||6 Jun 2008||25 Mar 2014||Agency For Science, Technology And Research||Immunoassay|
|US8681324||6 Mar 2013||25 Mar 2014||Bayer Healthcare, Llc||Method of differentiating between blood and control solutions containing a common analyte|
|US8691073 *||22 Aug 2011||8 Apr 2014||Bayer Healthcare Llc||Enzymatic electrochemical biosensor|
|US8696880 *||4 Feb 2005||15 Apr 2014||Bayer Healthcare Llc||Oxidizable species as an internal reference for biosensors and method of use|
|US8702926||11 Jul 2011||22 Apr 2014||Bayer Healthcare Llc||Oxidizable species as an internal reference in control solutions for biosensors|
|US8702965||22 Nov 2010||22 Apr 2014||Bayer Healthcare Llc||Biosensor methods having enhanced stability and hematocrit performance|
|US8716024||20 Nov 2012||6 May 2014||Bayer Healthcare Llc||Control solution for use in testing an electrochemical system|
|US8728299||14 Nov 2013||20 May 2014||Bayer Healthcare Llc||Biosensor performance increasing methods having enhanced stability and hematocrit performance|
|US8742063||26 May 2011||3 Jun 2014||Bayer Healthcare Llc||Polymer bonded redox molecules and methods of making the same|
|US8852422||6 Nov 2012||7 Oct 2014||Bayer Healthcare Llc||Concentration determination in a diffusion barrier layer|
|US8871069||6 Jun 2011||28 Oct 2014||Bayer Healthcare Llc||Low total salt reagent compositions and systems for biosensors|
|US8871070||19 Jul 2012||28 Oct 2014||Bayer Healthcare Llc||Systems, methods, and devices including amperometric and voltammetric duty cycles|
|US8871517||13 Dec 2013||28 Oct 2014||Bayer Healthcare Llc||Method of using a control solution and preparing for testing using the same|
|US8877035||28 Mar 2013||4 Nov 2014||Bayer Healthcare Llc||Gated amperometry methods|
|US8877344||23 Sep 2011||4 Nov 2014||Bayer Healthcare Llc||Radically polymerizable phenothiazine macromonomer for use in the coating of medical devices|
|US9005527||29 May 2013||14 Apr 2015||Bayer Healthcare Llc||Transient decay amperometry biosensors|
|US9039878||17 Dec 2012||26 May 2015||Bayer Healthcare Llc||Mediator for test sensor|
|US9110013||20 Dec 2013||18 Aug 2015||Bayer Healthcare Llc||Gated voltammetry methods|
|US9157111||21 Feb 2014||13 Oct 2015||Bayer Healthcare Llc||Method of making an electrochemical sensor strip|
|US9206460||3 Sep 2014||8 Dec 2015||Bayer Healthcare Llc||Concentration determination in a diffusion barrier layer|
|US9228978||14 Oct 2014||5 Jan 2016||Bayer Healthcare Llc||Identifying ionizable species with voltammetric duty cycles|
|US9233788||19 Jul 2012||12 Jan 2016||Bayer Healthcare Llc||Biosensor desiccant system having enhanced measurement performance|
|US9238717||23 Apr 2014||19 Jan 2016||Bayer Healthcare Llc||Polymer comprising a plurality of phenothiazine groups and methods of making the same|
|US9239312||14 Apr 2014||19 Jan 2016||Bayer Healthcare Llc||Methods of determining analyte concentration having enhanced stability and hematocrit performance|
|US9244078||29 Jan 2014||26 Jan 2016||Bayer Healthcare Llc||Oxidizable species as an internal reference in control solutions for biosensors|
|US20030031911 *||7 Aug 2002||13 Feb 2003||Rosalyn Ritts||Biocompatible membranes and fuel cells produced therewith|
|US20030039868 *||23 Aug 2002||27 Feb 2003||Liberatore Michael James||Enzymatic fuel cell|
|US20030049511 *||7 Aug 2002||13 Mar 2003||Rosalyn Ritts||Stabilized biocompatible membranes of block copolymers and fuel cells produced therewith|
|US20030094384 *||3 Sep 2002||22 May 2003||Vreeke Mark S.||Reagents and methods for detecting analytes, and devices comprising reagents for detecting analytes|
|US20030113606 *||7 Aug 2002||19 Jun 2003||Rosalyn Ritts||Biocompatible membranes of block copolymers and fuel cells produced therewith|
|US20030129469 *||15 Apr 2002||10 Jul 2003||Sun Hoi-Cheong Steve||Fuel cell with fuel concentrate metering|
|US20030175903 *||1 Nov 2002||18 Sep 2003||Ka-Yiu San||Recycling system for manipulation of intracellular NADH availability|
|US20040185517 *||29 Jan 2004||23 Sep 2004||Marfurt Karen L.||Method and test strip for determining glucose in blood|
|US20050170482 *||12 Nov 2004||4 Aug 2005||Rice University||Aerobic succinate production in bacteria|
|US20050266290 *||21 Apr 2005||1 Dec 2005||Powerzyme, Inc.||Enzymatic fuel cell with membrane bound redox enzyme|
|US20070045126 *||4 Feb 2005||1 Mar 2007||Beer Greg P||Oxidizable species as an internal reference for biosensors and method of use|
|US20070080073 *||22 Oct 2004||12 Apr 2007||Huang-Ping Wu||Enzymatic electrochemical biosensor|
|US20070246357 *||11 Apr 2007||25 Oct 2007||Huan-Ping Wu||Concentration Determination in a Diffusion Barrier Layer|
|US20070249028 *||14 Jun 2007||25 Oct 2007||Rice University||Aerobic Succinate Production in Bacteria|
|US20080009034 *||4 Jul 2007||10 Jan 2008||Rice University||Recycling System for Manipulation of Intracellular NADH Availability|
|US20080145878 *||12 Dec 2005||19 Jun 2008||Marfurt Karen L||Method of Differentiating Between Blood and Control Solutions Containing a Common Analyte|
|US20080156662 *||10 Sep 2007||3 Jul 2008||Bayer Healthcare Llc||Biosensor System Having Enhanced Stability And Hematocrit Performance|
|US20090014339 *||7 Apr 2006||15 Jan 2009||Beer Greg P||Oxidizable Species as an Internal Reference in Control Solutions for Biosensors|
|US20090068754 *||21 Oct 2007||12 Mar 2009||Bayer Healthcare Llc||Transient Decay Amperometry|
|US20090075389 *||6 Oct 2008||19 Mar 2009||Bayer Healthcare Llc||Method for determining an analyte in a fluid|
|US20090130698 *||10 May 2006||21 May 2009||Worden Robert M||Customizable and renewable nanostructured interface for bioelectronic applications|
|US20090145775 *||10 Dec 2008||11 Jun 2009||Bayer Healthcare Llc||Reagents and methods for detecting analytes|
|US20090148875 *||10 Dec 2008||11 Jun 2009||Jing Lin||Control markers for auto-detection of control solution and method of use|
|US20090171081 *||9 Dec 2008||2 Jul 2009||Bayer Healthcare Llc||Process of making 3-phenylimino-3h-phenothiazine or 3-phenylimino-3h-phenoxazine mediator|
|US20090176162 *||6 Apr 2007||9 Jul 2009||Ivan Exnar||Lithium rechargeable electrochemical cell|
|US20090178936 *||16 Jul 2009||Bayer Healthcare Llc||Porous Particle Reagent Compositions, Devices, and Methods for Biosensors|
|US20090246808 *||27 Mar 2008||1 Oct 2009||Wilsey Christopher D||Biosensor with improved analyte specificity|
|US20090305317 *||10 Dec 2009||Brauer Jacob S||User interface for testing device|
|US20100032316 *||10 Jul 2009||11 Feb 2010||Bayer Healthcare Llc||Systems and Methods Including Amperometric and Voltammetric Duty Cycles|
|US20100184195 *||12 Feb 2010||22 Jul 2010||Rice University||Recycling System for Manipulation of Intracellular NADH Availability|
|US20100267161 *||21 Oct 2010||Bayer Healthcare Llc||Multi-Region and Potential Test Sensors, Methods, and Systems|
|US20100300896 *||2 Dec 2010||Bayer Healthcare Llc||Redox Molecules And Methods Of Making The Same|
|US20100314248 *||16 Dec 2010||Worden Robert M||Renewable bioelectronic interface for electrobiocatalytic reactor|
|US20110115504 *||22 Nov 2010||19 May 2011||Bayer Healthcare Llc||Biosensor Methods Having Enhanced Stability and Hematocrit Performance|
|US20110189705 *||6 Jun 2008||4 Aug 2011||Zhiqiang Gao||Immunoassay|
|US20120037514 *||22 Aug 2011||16 Feb 2012||Bayer Healthcare Llc||Enzymatic Electrochemical Biosensor|
|EP0775699A1 *||12 Nov 1996||28 May 1997||Bayer Corporation||Method for the preparation of substituted 3-(phenylimino)-3H-phenothiazines and phenoxazines|
|EP0846948A1 *||26 Nov 1997||10 Jun 1998||Bayer Corporation||Mediators useful in an electrochemical biosensor|
|EP1293574A2 *||9 Sep 2002||19 Mar 2003||Bayer Corporation||Reagents, methods and devices for detecting analytes|
|EP1867732A1 *||9 Sep 2002||19 Dec 2007||Bayer Corporation||Reagents, methods and devices for detecting analytes|
|EP2535703A1||24 Sep 2008||19 Dec 2012||Bayer Healthcare LLC||Multi-electrode biosensor system|
|EP2535704A1||24 Sep 2008||19 Dec 2012||Bayer Healthcare LLC||Multi-electrode test method|
|EP2535705A1||24 Sep 2008||19 Dec 2012||Bayer Healthcare LLC||Multi-electrode test method|
|EP2535706A1||24 Sep 2008||19 Dec 2012||Bayer Healthcare LLC||Multi-electrode test sensor|
|EP2549270A2||19 Jul 2012||23 Jan 2013||Bayer Healthcare LLC||Biosensor desiccant system having enhanced measurement performance|
|EP2679150A2||15 Oct 2007||1 Jan 2014||Bayer HealthCare LLC||Transient decay amperometry|
|WO2005040407A1 *||22 Oct 2004||6 May 2005||Bayer Healthcare Llc||Enzymatic electrochemical biosensor|
|WO2005078118A1 *||4 Feb 2005||25 Aug 2005||Bayer Healthcare Llc||Oxidizable species as an internal reference for biosensors and method of use|
|WO2010077598A1||7 Dec 2009||8 Jul 2010||Bayer Healthcare Llc||Low total salt reagent compositions and systems for biosensors|
|WO2011059670A1||22 Oct 2010||19 May 2011||Bayer Healthcare Llc||Underfill recognition system for a biosensor|
|WO2011084607A1||16 Dec 2010||14 Jul 2011||Bayer Healthcare Llc||Transdermal systems, devices, and methods for biological analysis|
|WO2011150155A1||26 May 2011||1 Dec 2011||Bayer Healthcare Llc||Polymer bonded redox molecules and methods of making the same|
|WO2012040599A1||23 Sep 2011||29 Mar 2012||Bayer Healthcare Llc||Radically polymerizable phenothiazine macromonomer for use in the coating of medical devices|
|WO2013164590A1 *||29 Apr 2013||7 Nov 2013||Lifescan Scotland Limited||Enzymatic electrochemical-based sensors with nad polymeric coenzyme|
|WO2014114810A1||28 Jan 2014||31 Jul 2014||Roche Diagnostics Gmbh||Novel glucose oxidases derived from aspergillus niger|
|U.S. Classification||204/403.14, 435/817, 204/290.11, 204/290.06, 204/290.07|
|International Classification||G01N27/333, H01M4/90, C25B11/06, C12Q1/00, C07D279/20, G01N27/327, G01N27/416, C25B11/04, H01M8/16, C07D265/38|
|Cooperative Classification||Y02E60/527, Y10S435/817, C12Q1/004, H01M8/16, H01M4/9008|
|European Classification||C12Q1/00B4, H01M8/16, H01M4/90B|
|6 Jun 1995||AS||Assignment|
Owner name: BAYER CORPORATION, INDIANA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BLOCZYNSKI, MICHAEL L.;COREY, PAUL F.;DENG, YINGPING;ANDOTHERS;REEL/FRAME:007501/0692;SIGNING DATES FROM 19950522 TO 19950530
|21 Dec 1999||REMI||Maintenance fee reminder mailed|
|3 Feb 2000||FPAY||Fee payment|
Year of fee payment: 4
|3 Feb 2000||SULP||Surcharge for late payment|
|26 Nov 2003||FPAY||Fee payment|
Year of fee payment: 8
|28 Nov 2007||FPAY||Fee payment|
Year of fee payment: 12
|3 Dec 2007||REMI||Maintenance fee reminder mailed|
|23 Feb 2016||AS||Assignment|
Owner name: ASCENSIA DIABETES CARE HOLDINGS AG, SWITZERLAND
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BAYER HEALTHCARE LLC;REEL/FRAME:037880/0604
Effective date: 20160104